New compound offers hope for deadly tropical disease
A newly developed compound is showing promise in animal studies as a more effective treatment for human schistosomiasis, an understudied tropical disease caused by parasitic worms. The spread of schistosomiasis, a disease responsible for nearly 12,000 deaths globally each year, has been documented in 78 nations.
Although schistosomiasis transmission tends to occur in tropical and subtropical areas, climate change could shift it into new areas such as southern Europe. There is currently no vaccine available for the disease, which comes with severe clinical symptoms. The drug praziquantel is used for treatment. However, resistant mutations are reducing praziquantel’s efficacy, and the drug doesn’t kill the larval-stage parasites.

Sevan N. Alwan, an assistant professor at The University of Texas Health Science Center at San Antonio, led the research team.
“The infection can become reactivated when the larva develop into adult parasites, which comes with more severe symptoms and higher transmission rates,” said Alwan, an assistant professor at The University of Texas Health Science Center at San Antonio. “The compound we developed overcomes the limitations of praziquantel by being effective against the larval stage and resistant strains.”
Alwan will present the research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, which will be held March 23–26 in San Antonio.
“In recent reports, the cure rates for praziquantel were 60% in Sub-Saharan Africa, where the disease is highly endemic,” said Alwan. “The drug limitations strongly warrant the need for new therapeutics with a distinctly different mechanism of action to reach a better cure rate.”
The new compound was developed as part of the research team’s effort to design, synthesize and test reengineered derivatives of oxamniquine, which was previously used to treat patients with parasite but is no longer used due to drug resistance and limited effectiveness.
The researchers developed and tested 350 compounds. Five of these killed human Schistosoma species as well as a praziquantel-resistant strain in animal models.
One of these compounds, called CIDD-0149830, also killed larval parasites in experiments with cultured cells and a mouse model of the disease. In experimental groups of five female mice each, the number of larval worms was reduced by 71.7% with CIDD-0149830, while praziquantel reduced them by only 21.1%. The study also showed that CIDD-0149830 reduced the number of eggs more effectively.
“In addition to being effective against the larval stage and resistant strains, CIDD-0149830 also overcomes the limitation of oxamniquine by being effective against two major species of the parasite in animal models and can effectively treat mixed infection by these two species,” Alwan said.
Although the new results are promising, the researchers caution that they must still determine dosing for humans and perform safety and toxicity studies to make sure the treatment is safe for human use. They also plan to conduct experiments with male and female mice to assess whether sex influences the outcome of worm burden and morbidity.
Sevan N. Alwan will present this research during a poster session from 4:30 to 6:30 p.m. CDT on Sunday, March 24, in the exhibit hall of the Henry B. González Convention Center (Poster Board No. 56) (abstract).
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

CRISPR epigenome editor offers potential gene therapies
Scientists from the University of California, Berkeley, created a system to modify the methylation patterns in neurons. They presented their findings at ASBMB 2025.

Finding a symphony among complex molecules
MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.

E-cigarettes drive irreversible lung damage via free radicals
E-cigarettes are often thought to be safer because they lack many of the carcinogens found in tobacco cigarettes. However, scientists recently found that exposure to e-cigarette vapor can cause severe, irreversible lung damage.

Using DNA barcodes to capture local biodiversity
Undergraduate at the University of California, Santa Barbara, leads citizen science initiative to engage the public in DNA barcoding to catalog local biodiversity, fostering community involvement in science.

Targeting Toxoplasma parasites and their protein accomplices
Researchers identify that a Toxoplasma gondii enzyme drives parasite's survival. Read more about this recent study from the Journal of Lipid Research.

Scavenger protein receptor aids the transport of lipoproteins
Scientists elucidated how two major splice variants of scavenger receptors affect cellular localization in endothelial cells. Read more about this recent study from the Journal of Lipid Research.